{
    "name": "alectinib",
    "comment": "Rx",
    "other_names": [
        "Alecensa"
    ],
    "classes": [
        "Antineoplastics",
        "Tyrosine Kinase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/alecensa-alectinib-1000067",
    "pregnancy": {
        "common": [
            "Based on animal studies and its mechanism of action, can cause fetal harm when administered to a pregnant woman There are no available data on use in humans during pregnancy"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Administration to pregnant rats and rabbits by oral gavage during the period of organogenesis resulted in embryo-fetal toxicity and abortion at maternally toxic doses with exposures approximately 2.7-times those observed in humans treated with alectinib at 600 mg BID"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females: Use effective contraception during treatment and for 1 week after the final dose",
                    "Males: Use effective contraception during treatment and for 3 months following the final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Because of the potential for serious adverse reactions in breastfed infants from alectinib, advise a lactating woman not to breastfeed during treatment and for 1 week after the final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Elevated liver enzymes reported; monitor liver function tests including ALT, AST, and total bilirubin every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations (see Dosage Modifications)",
                "Interstitial lung disease (ILD) and pneumonitis reported; promptly investigate any patient who presents with worsening respiratory symptoms (eg, dyspnea, cough, fever) and immediately withhold treatment in patients diagnosed with ILD/pneumonitis (see Dosage Modifications)",
                "Severe myalgia and elevated CPK reported; advise patients to report any unexplained muscle pain, tenderness, or weakness; assess CPK levels q2weeks for the first month of treatment and as clinically indicated in patients reporting symptoms (see Dosage Modifications)",
                "Based on findings from animal studies and its mechanism of action, alectinib can cause fetal harm when administered to pregnant women (see Pregnancy)",
                "Renal impairment occurred; incidence of Grade â‰¥3 renal impairment was 1.7%, of which 0.5% were fatal events (see Dosage Modifications)",
                "Hemolytic anemia reported, including cases associated with a negative direct antiglobulin test (DAT) result; if hemolytic anemia is suspected, withhold therapy and initiate appropriate laboratory testing; if hemolytic anemia confirmed, consider resuming at a reduced dose upon resolution or permanently discontinue therapy"
            ],
            "specific": [
                {
                    "type": "Bradycardia",
                    "description": [
                        "Symptomatic bradycardia can occur; monitor heart rate and blood pressure regularly; dose modification is not required in cases of asymptomatic bradycardia",
                        "In cases of symptomatic bradycardia that is not life-threatening, withhold therapy until recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above and evaluate concomitant medications known to cause bradycardia, as well as anti-hypertensive medications",
                        "If attributable to a concomitant medication, resume therapy at a reduced dose; upon recovery to asymptomatic bradycardia or to a heart rate of 60 bpm or above, with frequent monitoring as clinically indicated",
                        "Permanently discontinue drug in case of recurrence; permanently discontinue drug in cases of life-threatening bradycardia if no contributing concomitant medication is identified"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Anemia",
            "percent": "56"
        },
        {
            "name": "Increased AST",
            "percent": "51"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "47"
        },
        {
            "name": "Increased CPK",
            "percent": "43"
        },
        {
            "name": "Fatigue",
            "percent": "26-41"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "39"
        },
        {
            "name": "Hyperglycemia",
            "percent": "36"
        },
        {
            "name": "Increased ALT",
            "percent": "34"
        },
        {
            "name": "Constipation",
            "percent": "34"
        },
        {
            "name": "Hypocalcemia",
            "percent": "32"
        },
        {
            "name": "Edema",
            "percent": "22-30"
        },
        {
            "name": "Hypokalemia",
            "percent": "29"
        },
        {
            "name": "Myalgia",
            "percent": "23-29"
        },
        {
            "name": "Increased creatinine",
            "percent": "28"
        },
        {
            "name": "Lymphopenia",
            "percent": "22"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "21"
        },
        {
            "name": "Hyponatremia",
            "percent": "20"
        },
        {
            "name": "Cough",
            "percent": "19"
        },
        {
            "name": "Rash",
            "percent": "15-18"
        },
        {
            "name": "Nausea",
            "percent": "14-18"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Diarrhea",
            "percent": "12-16"
        },
        {
            "name": "Dyspnea",
            "percent": "16"
        },
        {
            "name": "Back pain",
            "percent": "12"
        },
        {
            "name": "Vomiting",
            "percent": "7-12"
        },
        {
            "name": "Bradycardia",
            "percent": "11"
        },
        {
            "name": "Increased weight",
            "percent": "11"
        },
        {
            "name": "Vision disorder",
            "percent": "10"
        },
        {
            "name": "Increased ALT",
            "percent": "4.8"
        },
        {
            "name": "Increased CPK",
            "percent": "4.6"
        },
        {
            "name": "Lymphopenia",
            "percent": "4.6"
        },
        {
            "name": "Vision disorders",
            "percent": "4.6"
        },
        {
            "name": "Hypokalemia",
            "percent": "4"
        },
        {
            "name": "Renal impairment",
            "percent": "3.9"
        },
        {
            "name": "Dyspnea",
            "percent": "3.6"
        },
        {
            "name": "Increased AST",
            "percent": "3.6"
        },
        {
            "name": "Dysgeusia",
            "percent": "3.3"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "2.8"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "2.4"
        },
        {
            "name": "Hyperglycemia",
            "percent": "2"
        },
        {
            "name": "Hyponatremia",
            "percent": "2"
        },
        {
            "name": "Anemia",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": "1.2"
        },
        {
            "name": "Myalgia",
            "percent": "1.2"
        },
        {
            "name": "Diarrhea",
            "percent": "1.2"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "1.2"
        },
        {
            "name": "Edema",
            "percent": "0.7-0.8"
        },
        {
            "name": "Headache",
            "percent": "0.8"
        },
        {
            "name": "Rash",
            "percent": "0.4-0.7"
        },
        {
            "name": "Dysgeusia",
            "percent": "0.7"
        },
        {
            "name": "Nausea",
            "percent": "0.7"
        },
        {
            "name": "Vomiting",
            "percent": "0.4"
        },
        {
            "name": "Increased weight",
            "percent": "0.4"
        },
        {
            "name": "Hypocalcemia",
            "percent": "0.4"
        },
        {
            "name": "Hemolytic anemia",
            "percent": null
        }
    ]
}